Relacorilant Plus Nab-Paclitaxel Significantly Improves Survival in PROC

Top 5 Takeaways on Advances in Rare Melanoma Management

NEW VIDEO Videos Trending  

Updates at ASCO GU 2026
Enfortumab Vedotin Combo Boosts MIBC Survival Outcomes in EV-304 Trial

Data Show Comparable Immunotherapy Outcomes Across RCC Age Populations

Examining Pembrolizumab Combo Safety in High-Risk Prostate Cancer

Cabazitaxel Combo Does Not Significantly Improve Prostate Cancer Survival
 

Education Alert
How Are ADCs Shaping the Future of Early Breast Cancer Care? Latest Insights and Emerging Strategies
0.50 CPD
Did you know that, while well established in the metastatic setting, second-generation antibody-drug conjugates (ADCs) are now moving into the early setting?

Subcutaneous Amivantamab Earns Breakthrough Therapy Designation in HNSCC

Neoadjuvant Chemo/Nivolumab Yields Deep Responses in Borderline-Resectable PDAC Subset

NEW VIDEO Videos
 
Trending

Education Alert
Communicating to Enhance Care Through Data and Patient Experience: ER-Positive/HER2-Negative Metastatic Breast Cancer Edition
0.50 CME / CE / ABIM MOC
Did you know that benefits of transitioning from fulvestrant to oral SERDs are fewer clinic visits and more patient independence?  

NCCN Publishes New Guidelines Focusing on Pediatric Rhabdomyosarcoma

Men With Learning Disabilities Experience Worse Prostate Cancer Outcomes

Videos CAR-T 2.0: Expanding Access, Speed, and Precision
New Career Center Video:  
Learn how to balance clinical schedules with research, find mentorship, and take next steps in presenting your work with insights from Jonathan W. Lee, MD, MSc, and Chinmay Jani, MD.

Trending

FDA Grants RMAT Designation to HSV-Based Immunotherapy in NSCLC

FDA Grants Orphan Drug Designation to Zenocutuzumab in Cholangiocarcinoma

Videos What to Consider After Diagnosing a Patient With Ductal Carcinoma In Situ
New Career Center Video:   Learn how to balance clinical schedules with research, find mentorship, and take next steps in presenting your work with insights from Jonathan W. Lee, MD, MSc, and Chinmay Jani, MD.
Trending

BREAKING NEWS Data from the KEYNOTE-B96 trial support the FDA approval of the pembrolizumab regimen in these gynecologic malignancies.